New Insights into Pancreatic Cancer Progression and Potential Treatment Targets

A recent study from Brazil, published in Molecular and Cellular Endocrinology, has illuminated pathways by which pancreatic cancer spreads early in its progression. Led by researcher Carlos Alberto de Carvalho Fraga, the investigation focused on the interactions between resilient proteins and nerve tissues, revealing that a protein known as periostin, along with pancreatic stellate cells, plays a significant role in enabling cancer cells to invade surrounding nerves. This nerve invasion is closely associated with increased metastasis risk and the aggressive nature of pancreatic malignancies.

One crucial finding demonstrates that pancreatic tumors do not grow in isolation; they actively modify the surrounding healthy tissues to facilitate their own invasion. This complicates treatment efforts, as it explains why pancreatic cancer often eludes effective management once it begins to metastasize.

The Complexity of Pancreatic Cancer

Pancreatic adenocarcinoma, accounting for around 90% of pancreatic cancer cases, is renowned for its aggressiveness. Although it doesn't rank among the most common cancers, its lethality approaches its incidence, with approximately 510,000 new cases worldwide each year resulting in a similar number of deaths.

In Brazil alone, estimates from the National Cancer Institute suggest approximately 11,000 new cases and 13,000 deaths annually. "It's an aggressive cancer that's difficult to treat, with around 10% of patients surviving five years post-diagnosis," states oncologist Pedro Luiz Serrano Uson Junior, who co-authored the study.

Understanding Perineural Invasion

One of the most alarming characteristics of pancreatic cancer is perineural invasion, where cancer cells infiltrate nerves, causing intense pain and easing the tumor's ability to spread to other regions. "Perineural invasion is a marker of cancer aggressiveness," explains Uson, underlining the danger this poses for patient outcomes.

The research team utilized advanced genetic analysis tools to assess the activities of thousands of genes at high resolution, mapping their locations within tumor tissues. They examined 24 pancreatic cancer samples, discovering that the stroma—the connective tissue supporting the tumor—actively participates in the cancer's progression rather than acting as inert support.

The Role of Periostin

One of the study's pivotal discoveries involved the abundant production of periostin by pancreatic stellate cells. This protein dramatically alters the extracellular matrix—the structural framework of healthy tissue. Tumor cells exploit these modifications to navigate through tissue toward nearby nerves, a process calling upon specialized enzymes and resulting in extensive tissue disruption.

"Periostin plays a critical role in this remodeling, paving the way for tumor cells to invade," Nakaya believes. Following infiltration of nerves, these routes can act as conduits for tumor expansion.

According to the study, as the tumor environment evolves, it triggers a desmoplastic reaction, characterized by dense, fibrous tissue accumulation around the tumor, which complicates treatment efficacy. The generated stiffness hinders chemotherapy and immunotherapy drug penetration, allowing cancer cells to persist and proliferate.

This protective microenvironment is a key reason for the challenging treatment scenarios surrounding pancreatic cancer. "Perineural invasion indicates cancer cells have gained mobility," Uson states, explaining that many patients already present perineural invasion signs at diagnosis, typically revealed only after surgery.

Future Treatment Avenues

Given these findings, the research team's focus has turned to periostin as a promising therapeutic target. Their insights suggest that diminishing periostin activity or depleting its producing stellate cells might hinder nerve invasion and slow the expansive capabilities of pancreatic cancer. "Our work points to pathways that may chart future strategies in treating pancreatic cancer," Nakaya asserts.

Currently, clinical trials are underway examining antibodies aimed at inhibiting periostin in other cancer forms. Nakaya anticipates that these initiatives could offer insights into potential applications for pancreatic cancer treatment.

Uson emphasizes that identifying these treatment vectors aligns with the increasingly personalized landscape of oncology. "If we can develop specific antibodies or medications that target these stellate cells, we’ll have the means to counteract the tumor's invasive properties early on." He notes the absence of therapies focused specifically on perineural invasion, indicating a gap that future treatments could fill, potentially benefiting patients across various cancer types—including intestinal and breast cancers.

Beyond treatment targets, the study has demonstrated the efficacy of advanced data analysis drawn from public databases, unlocking new analytical possibilities previously unconsidered. "We answered questions the original researchers may have overlooked," Nakaya notes.

The next phase involves translating these findings into treatments effective before invasion commences. "Precision medicine is progressing, and soon, treatments will be tailored based on genomic and molecular alterations, rather than exclusively by tumor type," Uson concludes, indicating a significant shift forward in cancer care.

Materials provided by Fundação de Amparo à Pesquisa do Estado de São Paulo. Note: Content may be edited for style and length.